Condition: Rheumatoid Arthritis (RA) · Sponsor: Toll Biotech Co. Ltd. (Beijing)
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid arthritis (RA), who have had inadequate response to or intolerance of at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) . Participants will take the assigned study drug (either tollB-001 Tablets or placebo) once daily orally for 4 weeks, follow up for 1 week.
This description comes directly from the study's public registry record.
Weili Wang · +86 10 80710966 · wangweili@toll-biotech.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Recruiting |
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Puyang Oilfield General Hospital | Puyang, Henan, China | Recruiting |
| Affiliated Hospital of Inner Mongolia Medical University | Hohhot, Inner Mongolia, China | Recruiting |
| Pingxiang People's Hospital | Pingxiang, Jiangxi, China | Recruiting |
| Linfen Central Hospital | Linfen, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07408024